Eli Lilly says its diabetes drug tirzepatide gets approval in China

SHANGHAI, May 21 (Reuters) – Eli Lilly said on Tuesday its tirzepatide drug has received approval from Chinese regulators for use to treat type 2 diabetes.

Tirzepatide is the active ingredient in the U.S. firm’s diabetes drug Mounjaro and weight-loss drug Zepbound. (Reporting by Andrew Silver; Editing by Muralikumar Anantharaman)

(c) Copyright Thomson Reuters 2024. Click For Restrictions – https://agency.reuters.com/en/copyright.html